U.S. patent application number 17/146010 was filed with the patent office on 2021-05-06 for method and compositions for treatment and prevention of broad spectrum virus ailments comprising a calcium channel blocker or a calmodulin blocker.
This patent application is currently assigned to DR. KENNETH ADAMS MEDICINE PROFESSIONAL CORPORATION. The applicant listed for this patent is DR. KENNETH ADAMS MEDICINE PROFESSIONAL CORPORATION. Invention is credited to Kenneth W. Adams.
Application Number | 20210128514 17/146010 |
Document ID | / |
Family ID | 1000005329765 |
Filed Date | 2021-05-06 |
United States Patent
Application |
20210128514 |
Kind Code |
A1 |
Adams; Kenneth W. |
May 6, 2021 |
METHOD AND COMPOSITIONS FOR TREATMENT AND PREVENTION OF BROAD
SPECTRUM VIRUS AILMENTS COMPRISING A CALCIUM CHANNEL BLOCKER OR A
CALMODULIN BLOCKER
Abstract
In the broadest aspect, the invention provides a composition for
and a method of prophylactic and/or therapeutic treatment of a
animal/mammal for any viral disease, mixed bacterial and viral
infections, bacterial infections, bacterial endotoxins, bacterial
exotoxins, autoimmune diseases, and cellular or humoral mediated
allergic conditions that is caused by any virus that relies on the
maintenance of specific calcium ion concentrations for the post
ribosomal RNA synthesis processing of viral protein translation,
transportation and processing of viral structural components by
utilizing a therapeutic amount of a blocker selected from the group
consisting of a calcium channel blocker, a metabolite thereof, of
calmodulin blocker and a metabolite thereof, and a pharmaceutical
acceptable diluent or carrier, and/or is caused by damage to the
animal/mammal by a pathological immune response to antigens.
Inventors: |
Adams; Kenneth W.; (Toronto,
CA) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
DR. KENNETH ADAMS MEDICINE PROFESSIONAL CORPORATION |
Toronto |
|
CA |
|
|
Assignee: |
DR. KENNETH ADAMS MEDICINE
PROFESSIONAL CORPORATION
Toronto
CA
|
Family ID: |
1000005329765 |
Appl. No.: |
17/146010 |
Filed: |
January 11, 2021 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
16423225 |
May 28, 2019 |
10888541 |
|
|
17146010 |
|
|
|
|
13513639 |
Jun 4, 2012 |
10350190 |
|
|
PCT/CA2010/001926 |
Dec 3, 2010 |
|
|
|
16423225 |
|
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
A61K 31/5415 20130101;
A61K 31/00 20130101; A61K 31/4422 20130101; A61K 31/277 20130101;
A61K 31/554 20130101 |
International
Class: |
A61K 31/277 20060101
A61K031/277; A61K 31/00 20060101 A61K031/00; A61K 31/4422 20060101
A61K031/4422; A61K 31/5415 20060101 A61K031/5415; A61K 31/554
20060101 A61K031/554 |
Foreign Application Data
Date |
Code |
Application Number |
Dec 3, 2009 |
CA |
2687013 |
Claims
1. A pharmaceutical composition for treatment and prevention of
broad spectrum virus ailments comprising a blocker selected from
the group consisting of a calcium channel blocker, a metabolite
thereof, a calmodulin blocker and a metabolite thereof, and a
pharmaceutical acceptable diluent or carrier.
2. A composition as claimed in claim 1, wherein said calcium
channel blocker is verapamil.
3. A composition as claimed in claim 1, wherein said calcium
channel blocker is diltiazem.
4. A composition as claimed in claim 1, wherein said calcium
channel blocker is felodipine.
5. A composition as claimed in claim 1, wherein said calmodulin
blocker is trifluoperazine.
6. A composition as claimed in any one of claims 1 to 5, wherein
said composition is in the form of a cream, spray, mouth wash, gel,
ointment or patch.
7. A composition as claimed in any one of claims 1 to 5, wherein
said composition is in the form of a tablet, a sustained release
formulation for systemic use.
8. A composition as claimed in any one of claims 1 to 5, wherein
said composition is in the form of a sterile solution for
parenteral injection.
9. A method for the treatment and prevention of broad spectrum
virus ailments comprising administering to a human being a
composition comprising a blocker selected from the group consisting
of a calcium channel blocker, a metabolite thereof, a calmodulin
blocker and a metabolite thereof, and a pharmaceutical acceptable
diluent or carrier.
10. A method as claimed in claim 9, wherein said calcium channel
blocker is verapamil.
11. A method as claimed in claim 9, wherein said calcium channel
blocker is diltiazem.
12. A method as claimed in claim 9, wherein said calcium channel
blocker is felodipine.
13. A method as claimed in claim 9, wherein said calmodulin blocker
is trifluoperazine.
14. A method as claimed in claim 9, wherein said administration
comprises subcutaneous injection, high pressure jet device,
intracavernous injection, intravenous injection, intramuscular
injection, intradermal injection, intra-nasal or topical
administration.
15. A method as claimed in claim 12, wherein said administration is
topical administration.
16. A method of manufacturing a medicament intended for the
application of treating and preventing broad spectrum virus
ailments characterized in that said medicament comprises a blocker
selected from the group consisting of a calcium channel blocker, a
metabolite thereof, a calmodulin blocker and a metabolite thereof;
and admixed with a pharmaceutical acceptable diluent or
carrier.
17. A method as claimed in claim 16, wherein said blocker is
selected from verapamil, diltiazem, felodipine and trifluoperazine.
Description
FIELD OF THE INVENTION
[0001] The invention relates to methods and compositions for the
treatment and prevention of broad spectrum of viral ailments, mixed
bacterial and viral infections, bacterial infections, bacterial
endotoxins, bacterial exotoxins, autoimmune diseases, and cellular
or humoral mediated allergic conditions comprising a
therapeutically effective amount of a blocker selected from the
group consisting of a calcium channel blocker, a metabolite
thereof, a calmodulin blocker and a metabolite thereof, and a
pharmaceutical acceptable diluent or carrier.
SUMMARY OF THE INVENTION
[0002] A novel class of antiviral commands has now been discovered
which has been found to exhibit a particularly favorable broad
spectrum of antiviral properties through all classes of viruses.
The inventor has discovered that pharmaceutical compositions
comprising a blocker selected from the group consisting of calcium
channel blockers, metabolites thereof, calmodulin blockers and
metabolites thereof that have been used to treat medical conditions
unrelated to viral infections can effectively suppress
intracellular replication of multiple viral species and prevent and
treat diseases caused by a wide spectrum of acute or chronic viral
infection. In addition to direct antiviral effects due to the
suppression of viral replication and suppression of viral release
from infected host cells, the inventor has also observed that these
agents also have a beneficial inhibitory effect upon the host
immune response to suppress the severity of the host's immune
response to viral as well as other foreign antigens.
[0003] Since a significant portion of the pathologic damage done to
the host during an infection or other types pathological diseases
are a result damage to the host tissues from the immune systems
indiscriminant damage to healthy and often uninfected host cells
near or remote to the site of infection. These pharmaceutical
compositions comprising a blocker selected from the group
consisting of calcium channel blockers, metabolites thereof.
calmodulin blockers and metabolites thereof also help protect the
host from other exaggerated pathological conditions such as
bacterial infections, bacterial exotoxins and endotoxins.
[0004] As a result these agents afford special protective benefits
for isolated bacterial infections, mixed bacterial infections,
isolated vital infections, mixed viral infections,
mixed/combined/superimposed viral and bacterial infections.
[0005] As well these agents can be beneficial for other
non-infectious diseases or pathological states such as auto-immune
processes psoriasis, autoimmune thryoiditis, autoimmune neuritis,
autoimmune pericarditis, autoimmune pneumonitis, or any other type
of autoimmune process.
[0006] As well these agents can be beneficial for other
non-infectious diseases or pathological states such as cell
mediated allergic reactions to latex gloves, nickel or other metal
allergies, or any other pathological immune response.
[0007] These are all examples of pathological conditions in animals
of when the animals own immune response becomes excessive, and
instead of protecting the animal, is actually damaging to the
animal. This reduction in inflammation and damage to host is
theorized by the inventor to be potentially an inhibitory effect of
calcium channel blockers and calmodulin blockers on the movement
and migration of inflammatory cells involved in the host response
to these antigen into the sites of the pathologic or exaggerated
immune response.
[0008] Thus, the invention provides methods and compositions for
the treatment and prevention of broad spectrum infectious,
inflammatory and autoimmune ailments in human beings.
[0009] In the broadest aspect the invention provides a composition
for and a method of prophylactic and/or therapeutic treatment of a
mammal for any viral disease that is caused by any virus that
relies on the maintenance of specific calcium ion concentrations
for the past ribosomal RNA to protein translation transportation
and processing of viral structural components by utilizing a
therapeutic amount of a blocker selected from the group consisting
of a calcium channel blocker, a metabolite thereof, a calmodulin
blocker and a metabolite thereof, and a pharmaceutical acceptable
diluent or carrier.
[0010] Accordingly, in one aspect, the invention provides a
pharmaceutical composition for the treatment and prevention of
broad spectrum virus ailments, mixed bacterial and viral
infections, bacterial infections, bacterial endotoxins, bacterial
exotoxins, autoimmune diseases, and cellular or humoral mediated
allergic conditions in animals and human beings, said composition
comprising a therapeutically effective amount of a blocker selected
from the group consisting of a calcium channel blocker, a
metabolite thereof, a calmodulin blocker and a metabolite thereof,
and a pharmaceutical acceptable diluent or carrier.
[0011] Preferably, the calcium channel blocker is verapamil,
diltiazem or felodipine; and the calmodulin blocker is
trifluoperazine.
[0012] Preferably, the composition is in the form of a cream,
spray, aerosol, powder, liquid for nebulization, gel, ointment or
patch.
[0013] Preferably, the composition is in the form of a tablet, a
sustained release formulation for systemic use.
[0014] Preferably, the composition is in the form of a sterile
solution for parenteral injection.
[0015] In a still yet further aspect, the invention provides a
method of manufacturing a medicament intended for the prevention,
and treatment of viral infections characterized in that the
medicament is a blocker selected from the group consisting of a
calcium channel blocker, a metabolite thereof, a calmodulin blocker
and a metabolite thereof; and admixed with a pharmaceutical
acceptable diluent or carrier.
[0016] Preferably, the blocker is selected from verapamil,
diltiazem, felodipine and trifluoperazine.
[0017] Kits comprising pharmaceutical compositions of the invention
formulated in sterile unit dosage forms suitable for administration
to patients, includes instructions for use in written, oral,
videotape, compact disc, other digital electronic form, or other
recorded media, are contemplated.
[0018] Thus, in a further aspect, the invention provides a kit
comprising the above-described compositions and an instruction for
using the combination in treating, improving, curing or preventing
viral infections.
[0019] The appropriate dosage and frequency of treatment may vary
depending on the specific symptoms and signs exhibited by the
patient, or the clinical situation for prophylactic uses. Other
health related factors should also be considered.
DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS
[0020] In order that the invention may be better understood,
preferred embodiments will now be described by way of example only
with reference to the following Examples.
EXAMPLE 1
[0021] 53 year old male with symptoms of viral upper respiratory
infection started experiencing nasal congestion and nasal
discharge. Patient sprayed 0.2 ml of Verapamil 2 mg/ml into each
nostril and directly into the back of the throat. Within minutes,
patient experienced a reduction in nasal congestion and decreased
nasal discharge. The nasal continued to slow and stopped after
approximately 20 minutes.
[0022] After a couple of hours the patient then continued to apply
repeated small local applications of 0.1 ml intranasally and orally
to throat twice more when the symptoms of nasal congestion started
to recurred and again prior to going to sleep that night.
[0023] When the patient awoke the next day the upper respiratory
symptoms were cleared, but the patient began to experience lower
respiratory infectious symptoms of an increasingly productive cough
the next day. These lower respiratory symptoms worsened and by the
following day the patient was experiencing extreme uncontrolled
coughing episodes. The patient went on Verapamil 80 mg q6-8 hours.
Prior to starring Verapamil, the patient had profuse clear mucus
discharge from the lungs and was experiencing prolonged and
frequent coughing spells. After taking his first dose of Verapamil,
within 10-20 minutes the patient noticed a profound reduction in
coughing and a significant reduction in volume of sputum being
cleared from the lungs. Within 30-60 minutes of the first dose, the
cough was infrequent and mostly non-productive. For the next four
days, whenever the patient went beyond 6-8 hours of last 80 mg
dose, he began to experience increasing productive coughing
repeatedly demonstrating a relationship between declining serum
Verapamil levels and increasing severity of his
bronchitis/pulmonary symptoms and each time that the patient took
the 80 mg Verapamil tablet there was a dramatic reduction in
pulmonary discharge and reduction in coughing for over 6 hours
before symptoms.
EXAMPLE 2
[0024] Patient A with recurrent cold sores was given Diltizem 100
mg/ml and asked to apply topically at the first signs of a cold
sore. The patient observed that in the initial tingling phase prior
to the eruption if he applied the cream, the infection could be
prevented and if application was delayed until eruption was
visible, he could minimize the severity, reduce the size and
complete healing clearance would occur in 2-4 days instead of
lasting the usual 7 days.
EXAMPLE 3
[0025] Patient B with recurrent cold sores was given Verapamil 200
mg/ml and asked to apply at the first signs of a cold sore. The
patient observed that in the initial tingling phase if he applied
the cream, the infection could be prevented and if application was
delayed until eruption was visible, he could minimize the severity,
reduce the size and complete healing clearance could occur in 2-4
days instead of lasting the usual 7 days.
EXAMPLE 4
[0026] Male patient with a long history of recurrent Genital Herpes
was using Diltiazem. When questioned by the inventor about the
frequency of recurrences of his genital herpes before and after
starting Diltiazem, the patient reported that before he was having
several episode per year, and that after starting Diltiazem there
had been only about 1-2 episodes per year, that they were much
smaller and seemed to heal much quicker when on when Diltiazem.
EXAMPLE 5
[0027] HIV patient took Verapamil 240 mg (120 mg of verapamilSR)
twice daily for 2 weeks before repeat blood work and showed
significant rise in T4 helper counts.
EXAMPLE 6
[0028] A 39 year old woman with a three day history of fever,
chills, muscle aches and nausea. On the second and third days the
patient developed increasing diarrhea. On the morning of the third
day the patient was experiencing loose, watery stools with a cramps
and lower abdominal pain. Patient had 6 watery bowel movements and
was going to the washroom frequently before starting Verapamil 120
mg tablets, taking one every 8 hours. Within one hour of taking the
first Verapamil, the abdominal cramping began subsiding and her
stools began to become more formed and diarrhea improved.
EXAMPLE 7
[0029] Elderly patient with Herpes Zoster infection on the upper
left abdomen. Patient took Verapamil 120 mg SR twice daily and
noted reduced pain, reduced rash and rapid healing of lesions.
[0030] Although this disclosure has described and illustrated
certain preferred embodiments of the invention, it is to be
understood that the invention is not restricted to those particular
embodiments. Rather, the invention includes all embodiments which
are functional or mechanical equivalent of the specific embodiments
and features that have been described and illustrated.
EXAMPLE 8
[0031] A 54 year old male surgeon with a latex glove allergy.
Symptoms of a red eczematous rash develops when he uses latex
gloves. This delayed hypersensitivity reaction is prevented by the
application of Verapamil 200 mg/ml ointment prior to wearing latex
gloves.
[0032] Also the chronic rash that occurs from daily expose to latex
was seen to improved within hours of the application of verapamil
200 mg/ml ointment.
EXAMPLE 9
[0033] 64 year old female with Rheumatoid Arthritis and significant
pain and disability in her hands noted a significant reduction of
pain in her hand within hours of applying Verapamil or Diltiazem
ointments. And patient reported improved mobility of joints with
sustained applications over several days.
* * * * *